Rare Diseases Clinical Trial
Official title:
Finding Genes for Rare Diseases
This study will help the investigator understand the pathogenesis of different rare genetic
conditions and to establish database of rare genetic databases. This would ultimately help to
provide more accurate diagnosis through advanced genomic diagnostic testing and databases
established from this study. This knowledge would in turn help in the clinical management of
other affected family members and other individuals affected with similar conditions.
Understanding of pathogenesis of the disease would also enable the investigator to develop
targeted therapies for rare genetic diseases, and also to collaborate on the targeted
therapy-related clinical trials.
The investigator plans to store the results of this study in databases. These results will be
shared with other researchers or doctors, who research, diagnose or treat the individuals
with similar diseases.
The investigator will only share the data that is collected and not the biological samples.
This proposed study is designed identify for the genetic causes of rare diseases. This study
does not involve the use of investigational medication or devices. No randomization will take
place. Participants enrolled into the study will be asked to provide blood or saliva samples
for DNA testing. Samples will be collected by one of two methods;
- If the participant has had a clinical genetic test performed, the results/data will be
collected from the University of Kentucky (UK) clinical molecular pathology laboratory
or from the medical records. If the cause of the disease is not identified on clinical
genetic testing, the investigator will reanalyze the clinical genetic testing data or
use the blood or saliva sample leftover from the clinical genetic testing for additional
experiments using new methods to identify the cause of the disease.
- If no sample leftover from the clinical genetic testing is available, the investigator
plans to collect about 2 teaspoons of blood or saliva from the participant at their
first visit to the site.
This study plans to enroll 1000 participants from the University of Kentucky Medical Center.
The investigator plans to store any blood or saliva DNA samples collected for future research
studies involving rare genetic diseases. The stored blood or saliva DNA samples will not be
released to anyone outside the study.
Stored samples will be labeled with a unique study identifier and will be maintained in the
investigator's research laboratory located at the University of Kentucky, Department of
Pathology and Laboratory Medicine, 800 Rose Street, Lexington, KY 40536.
There is no limit on the length of time that the samples will be stored. The investigator may
keep using the stored samples indefinitely unless the participant decide to withdraw from the
project.
Participants may withdraw or cancel their permission for the use for their stored samples at
any time. However, any samples and health information already obtained from their use will
not be destroyed.
There will be no additional costs or charges to the participant for allowing the investigator
to store and use their left over blood or saliva samples and there is no benefit to the
participant for allowing the investigator to store their samples.
Participants will not be paid for donating their samples. The samples and information that
the participants are donating will no longer belong to them. The research may lead to new
medical knowledge, tests, treatments or products. These products could have some financial
value. There are no plans to provide financial payment to either the participant or their
relatives should this occur.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05794217 -
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
|
||
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Completed |
NCT03290469 -
NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants
|
N/A | |
Not yet recruiting |
NCT05955794 -
Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes
|
N/A | |
Recruiting |
NCT04429750 -
Intact Cord Resuscitation in CDH
|
N/A | |
Not yet recruiting |
NCT04152876 -
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
|
||
Recruiting |
NCT03683966 -
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
|
||
Not yet recruiting |
NCT04319796 -
European Registry on Rare Neurological Diseases
|
||
Completed |
NCT02736565 -
Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT05070988 -
Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
|
||
Completed |
NCT03563677 -
Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases
|
N/A | |
Recruiting |
NCT05499091 -
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
|
N/A | |
Completed |
NCT03954652 -
Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"
|
N/A | |
Recruiting |
NCT05703893 -
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
|
||
Enrolling by invitation |
NCT04703179 -
Rare and Undiagnosed Disease Research Biorepository
|
||
Recruiting |
NCT04024774 -
Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
|
||
Recruiting |
NCT06343558 -
Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
|
||
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Enrolling by invitation |
NCT04654000 -
Rheopheresis as Adjuvant Treatment of Calciphylaxis
|
N/A | |
Recruiting |
NCT04651439 -
Severe Bullous Drug Eruption and Filgrastim
|
Phase 2/Phase 3 |